253 related articles for article (PubMed ID: 21787175)
1. Prasugrel resistance: fact or fiction.
Alexopoulos D
Platelets; 2012; 23(2):83-90. PubMed ID: 21787175
[TBL] [Abstract][Full Text] [Related]
2. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study.
Trenk D; Stone GW; Gawaz M; Kastrati A; Angiolillo DJ; Müller U; Richardt G; Jakubowski JA; Neumann FJ
J Am Coll Cardiol; 2012 Jun; 59(24):2159-64. PubMed ID: 22520250
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the degree of platelet aggregation inhibition with prasugrel versus clopidogrel and clinical outcomes in patients with unprotected left main disease treated with everolimus-eluting stents.
Migliorini A; Valenti R; Parodi G; Marcucci R; Abbate R; Carrabba N; Gensini GF; Antoniucci D
Am J Cardiol; 2013 Dec; 112(12):1843-8. PubMed ID: 24063827
[TBL] [Abstract][Full Text] [Related]
4. Prasugrel offers consistent platelet control in appropriate patients requiring treatment.
Aalbers J
Cardiovasc J Afr; 2011; 22(2):107, 109. PubMed ID: 21556460
[No Abstract] [Full Text] [Related]
5. The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses.
Judge HM; Buckland RJ; Sugidachi A; Jakubowski JA; Storey RF
Platelets; 2008 Mar; 19(2):125-33. PubMed ID: 18297550
[TBL] [Abstract][Full Text] [Related]
6. The onset of inhibition of platelet aggregation with prasugrel compared with clopidogrel loading doses using gatekeeping analysis of integrated clinical pharmacology data.
Zhu B; Effron MB; Kulkarni MP; Li YG; Jakubowski JA; Miller DL; Baker BA; Luo J; Small DS; Winters KJ
J Cardiovasc Pharmacol; 2011 Mar; 57(3):317-24. PubMed ID: 21266916
[TBL] [Abstract][Full Text] [Related]
7. Resistance to anti-platelet agents.
Cattaneo M
Thromb Res; 2011 Feb; 127 Suppl 3():S61-3. PubMed ID: 21262444
[TBL] [Abstract][Full Text] [Related]
8. The influence of P2Y12 receptor deficiency on the platelet inhibitory activities of prasugrel in a mouse model: evidence for specific inhibition of P2Y12 receptors by prasugrel.
Hashimoto M; Sugidachi A; Isobe T; Niitsu Y; Ogawa T; Jakubowski JA; Asai F
Biochem Pharmacol; 2007 Oct; 74(7):1003-9. PubMed ID: 17681285
[TBL] [Abstract][Full Text] [Related]
9. Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species.
Niitsu Y; Sugidachi A; Ogawa T; Jakubowski JA; Hashimoto M; Isobe T; Otsuguro K; Asai F
Eur J Pharmacol; 2008 Jan; 579(1-3):276-82. PubMed ID: 17996866
[TBL] [Abstract][Full Text] [Related]
10. Advances in the monitoring of anti-P2Y12 therapy.
Harrison P
Platelets; 2012; 23(7):510-25. PubMed ID: 22916724
[TBL] [Abstract][Full Text] [Related]
11. Comparison of patient intake of ticagrelor, prasugrel, or clopidogrel on restoring platelet function by donor platelets.
Scharbert G; Wetzel L; Schrottmaier WC; Kral JB; Weber T; Assinger A
Transfusion; 2015 Jun; 55(6):1320-6. PubMed ID: 25641006
[TBL] [Abstract][Full Text] [Related]
12. Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.
Mousa SA; Jeske WP; Fareed J
Clin Appl Thromb Hemost; 2010 Apr; 16(2):170-6. PubMed ID: 20299391
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor.
Dobesh PP
Pharmacotherapy; 2009 Sep; 29(9):1089-102. PubMed ID: 19698014
[TBL] [Abstract][Full Text] [Related]
14. Prasugrel reduces agonists' inducible platelet activation and leukocyte-platelet interaction more efficiently than clopidogrel.
Gremmel T; Eslam RB; Koppensteiner R; Lang IM; Panzer S
Cardiovasc Ther; 2013 Oct; 31(5):e40-5. PubMed ID: 23311679
[TBL] [Abstract][Full Text] [Related]
15. Mode of action of P2Y(12 ) antagonists as inhibitors of platelet function.
Iyú D; Glenn JR; White AE; Fox SC; van Giezen H; Nylander S; Heptinstall S
Thromb Haemost; 2011 Jan; 105(1):96-106. PubMed ID: 20941457
[TBL] [Abstract][Full Text] [Related]
16. The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration.
Jakubowski JA; Payne CD; Li YG; Brandt JT; Small DS; Farid NA; Salazar DE; Winters KJ
Thromb Haemost; 2008 Feb; 99(2):409-15. PubMed ID: 18278193
[TBL] [Abstract][Full Text] [Related]
17. A randomized trial of platelet reactivity monitoring-adjusted clopidogrel therapy versus prasugrel therapy to reduce high on-treatment platelet reactivity.
Bonello L; Laine M; Baumstarck K; Fernandez J; Maillard L; Peyrol M; Bessereau J; Aradi D; Camilleri E; Roubille F; Piot C; Paganelli F; Camoin-Jau L; Dignat-George F
Int J Cardiol; 2013 Oct; 168(4):4244-8. PubMed ID: 23911273
[TBL] [Abstract][Full Text] [Related]
18. Platelet P2 receptors: old and new targets for antithrombotic drugs.
Cattaneo M
Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):45-55. PubMed ID: 17187456
[TBL] [Abstract][Full Text] [Related]
19. A prospective randomized trial comparing the recovery of platelet function after loading dose administration of prasugrel or clopidogrel.
Bernlochner I; Morath T; Brown PB; Zhou C; Baker BA; Gupta N; Jakubowski JA; Winters KJ; Schömig A; Kastrati A; Sibbing D
Platelets; 2013; 24(1):15-25. PubMed ID: 22372531
[TBL] [Abstract][Full Text] [Related]
20. Point-of-care platelet reactivity determination with VerifyNow-P2Y12 following administration of clopidogrel or prasugrel: data from a real-world, clinical care inpatient setting.
Bae JP; Candrilli SD; Fortenberry J; Meyers JL; Jakubowski JA; Drenning D
Hosp Pract (1995); 2014 Oct; 42(4):7-15. PubMed ID: 25502126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
